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Infective endocarditis (IE) is a life-threatening condition with a 50% requirement for early 
cardiac surgery and 30% mortality at 1 year.1  We have recently used publicly available 
annual admission data for hospitals in England https://digital.nhs.uk/data-and-
information/publications/statistical/hospital-admitted-patient-care-activity, to examine the 
incidence of IE admissions (primary ICD-10 diagnostic code I33) between 1998-2019.  These 
data demonstrate stable incidence between 1998-9 (26·6 cases/million) and 2009-10 (26·9 
cases/million) but an 86% increase to 50·0 cases/million in 2018-19 (Figure). 
 
One hypothesised cause of IE is oral pathogens entering the bloodstream during invasive 
dental procedures.  Consequently, use of antibiotic prophylaxis (AP) prior to invasive dental 
procedures in at risk patients is a long-held preventive measure - but its use remains 
controversial. Since 2007, international guidelines have recommended that AP should be 
restricted to patients at highest-risk of adverse outcome (those with a previous history of IE, 
prosthetic or repaired heart valves, or complex congenital heart disease), reflecting a lack of 
evidence for AP efficacy, concerns for risk of adverse drug reactions, and the possibility that 
AP contributes to an ever-increasing global burden of antibiotic resistance. In March 2008, 
however, the National Institute for Health and Care Excellence (NICE) boldly recommended 
complete cessation of AP to prevent IE in the UK, thereby creating conditions for a natural 
experiment of its efficacy. 
 
In 2014, our paper in this journal2 demonstrated a large and significant (p<0·0001) fall in AP 
prescribing in England following implementation of NICE guidance and a parallel significant 
increase in IE incidence (p<0·0001) beyond the preceding upward trend; by March 2013, 
there were 35 extra cases of IE per month (419 per annum).2  Since then, NICE has 
acknowledged public and professional concern, and adjusted wording of their guidance to 
indicate that AP is not ‘routinely’ recommended (https://www.nice.org.uk/guidance/cg64).3  
This subtle change, however, failed to define routine versus non-routine and has caused 
confusion for dentists, cardiologists and their patients. In response, the Scottish Dental 
Clinical Effectiveness Programme (SDCEP) produced advice for dentists on clinical 
implementation of the NICE guidelines (http://www.sdcep.org.uk/published-
guidance/antibiotic-prophylaxis/). Key points include explanation of the risk of developing IE 
after invasive dental procedures to those at increased-risk, clarification of the risks and 
benefits of AP, and empowerment of individual patients to determine whether or not they 
receive AP. Although endorsed by NICE and the British Cardiovascular Society, this advice 
has not been widely publicised and is not referred to in the NICE guidelines, hence most 
dentists remain unaware of it or are confused about its implementation. 
 
In the absence of microbiological data, the rapidly increasing incidence of IE in England 
cannot be attributed solely to cessation of AP in the wake of NICE recommendations.  
Indeed, multiple contributory factors may be implicated, including an ageing population 
with associated comorbidities, increased use of intra-cardiac devices (permanent 
pacemakers, implantable cardioverter-defibrillators, surgical and transcatheter heart valves) 
and vascular interventions (including haemodialysis in the growing population with chronic 
renal failure), epidemic levels of injection drug use and increased diagnostic awareness of 
IE.  The emergence of staphylococci and enterococci (neither of which are targeted by 
current AP strategies) as common causes of nosocomial infection could also have 
contributed to this increase.  Nevertheless, these findings are disturbing and contrast with 
reports of falling incidence in the US 4-7 and falling or more modest increases in Europe,8-10 
where contributory factors are likely to be similar to those in England. Greater public health 
awareness and further investigation of the causes of this alarming increase in IE incidence in 
England are warranted alongside renewed emphasis on education of patients at risk, 
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